Global Muscle Relaxant Drugs Market to Grow at a CAGR of 5.64%, 2017-2021 With Pfizer, Ipsen Group, Allergan, Novartis & Teva Pharmaceuticals Dominating - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Muscle Relaxant Drugs Market 2017-2021" report to their offering.

The global muscle relaxant drugs market to grow at a CAGR of 5.64% during the period 2017-2021.

The report, Global Muscle Relaxant Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is anti-aging treatments driving adoption of facial relaxants. The demand for anti-aging treatments is expected to drive the market growth. The increasing adoption of such treatments is due to the growing older population as baby boomers drive the demand. These individuals are more focused on drugs that target specific problems caused by aging such as wrinkles, which require facial muscle relaxants for the treatment. Wrinkles occur due to the stiffness in muscles. Consumers, especially the older population, are looking for products to maintain and improve their appearance.

Currently, out of the total population in the world, those aged above 65 years form the fastest-growing population group, accounting for 8.1% of the total population in 2014. This share is expected to reach 16% by 2050. The rise in the aging population is expected to drive the demand for facial muscle relaxants. Furthermore, younger individuals are making changes in their lifestyles to maintain youthful-looking skin. This scenario is likely to change the market dynamics in the future.

Key vendors

  • Pfizer
  • Ipsen Group
  • Allergan
  • Novartis
  • Teva Pharmaceuticals

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview of muscle spasticity and spasms

PART 06: Pipeline landscape

PART 07: Market landscape

PART 08: Market segmentation by product category

PART 09: Geographical segmentation

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

PART 15: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/st8zcl/global_muscle

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Musculoskeletal Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Musculoskeletal Disorders Drugs